A review of eslicarbazepine acetate (Stedesa®)

Cristofer Price; Melody Ryan

doi:10.9740/mhc.n127372

A review of eslicarbazepine acetate (Stedesa®)

Cristofer Price, Melody Ryan

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Eslicarbazepine acetate is an anticonvulsant medication approved in Europe for adjunctive therapy in adults with partial-onset seizures. FDA approval is expected shortly for use in the United States. This article reviews the pharmacologic and pharmacokinetic profile of eslicarbazepine acetate, and factors that should be considered when using this medication.

Original language	English
Pages (from-to)	111-114
Number of pages	4
Journal	Mental Health Clinician
Volume	2
Issue number	5
DOIs	https://doi.org/10.9740/mhc.n127372
State	Published - Nov 1 2012

Bibliographical note

Publisher Copyright:
© 2012 Allen Press Inc.. All Rights Reserved.

Keywords

anticonvulsant
eslicarbazepine acetate

ASJC Scopus subject areas

Neuropsychology and Physiological Psychology
General Pharmacology, Toxicology and Pharmaceutics
Clinical Neurology
Pharmacology (medical)

Access to Document

10.9740/mhc.n127372

Cite this

@article{bb3f643e7113433fbcf71ca50b20198b,

title = "A review of eslicarbazepine acetate (Stedesa{\textregistered})",

abstract = "Eslicarbazepine acetate is an anticonvulsant medication approved in Europe for adjunctive therapy in adults with partial-onset seizures. FDA approval is expected shortly for use in the United States. This article reviews the pharmacologic and pharmacokinetic profile of eslicarbazepine acetate, and factors that should be considered when using this medication.",

keywords = "anticonvulsant, eslicarbazepine acetate",

author = "Cristofer Price and Melody Ryan",

year = "2012",

month = nov,

day = "1",

doi = "10.9740/mhc.n127372",

language = "English",

volume = "2",

pages = "111--114",

journal = "Mental Health Clinician",

issn = "2168-9709",

publisher = "Allen Press Inc.",

number = "5",

}

TY - JOUR

T1 - A review of eslicarbazepine acetate (Stedesa®)

AU - Price, Cristofer

AU - Ryan, Melody

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Eslicarbazepine acetate is an anticonvulsant medication approved in Europe for adjunctive therapy in adults with partial-onset seizures. FDA approval is expected shortly for use in the United States. This article reviews the pharmacologic and pharmacokinetic profile of eslicarbazepine acetate, and factors that should be considered when using this medication.

AB - Eslicarbazepine acetate is an anticonvulsant medication approved in Europe for adjunctive therapy in adults with partial-onset seizures. FDA approval is expected shortly for use in the United States. This article reviews the pharmacologic and pharmacokinetic profile of eslicarbazepine acetate, and factors that should be considered when using this medication.

KW - anticonvulsant

KW - eslicarbazepine acetate

UR - http://www.scopus.com/inward/record.url?scp=85064428284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064428284&partnerID=8YFLogxK

U2 - 10.9740/mhc.n127372

DO - 10.9740/mhc.n127372

M3 - Review article

AN - SCOPUS:85064428284

SN - 2168-9709

VL - 2

SP - 111

EP - 114

JO - Mental Health Clinician

JF - Mental Health Clinician

IS - 5

ER -

A review of eslicarbazepine acetate (Stedesa®)

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this